This stock is making smart investments in biotech -- and not just through partnerships, but through actual equity investments in biotechs like Regeneron (REGN +0.10%) and Alnylam Pharmaceuticals (ALNY 1.15%). It's a smart play for income investors (3.5% dividend yield) and growth investors alike.
Of course, there are threats and headwinds -- what company doesn't have them? -- but in the video below, Motley Fool health care analysts Michael Douglass and David Williamson reveal why Sanofi (SNY 1.82%) is their favorite European pharma stock.
